

13 December 2017

ePAT Technologies Limited
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290
ianhobson@bigpond.com

Excellent performance of PainChek™ confirmed in second peer-review paper

Highlights:

- Second study confirms excellent clinical performance of PainChek™
- 400 paired assessments in 34 residents showed PainChek™ has excellent validity and reliability properties, compared to the standard Abbey Pain Scale.
- The study to be published in *Dementia and Geriatric Cognitive Disorders* confirms previous clinical findings published in the *Journal of Alzheimer's Disease (JAD)* Another study demonstrating the excellent clinical performance of PainChek™ has been accepted for publication in *Dementia and Geriatric Cognitive Disorders*, a prestigious and top tier peer reviewed journal devoted to the study of cognitive dysfunction in preclinical and clinical studies. The study which used a later version of App confirmed the positive findings (including excellent validity and reliability) previously published in the *Journal of Alzheimer's Disease (JAD)* in August, 2017.


The study included 400 paired assessments in 34 people with moderate to severe dementia (aged 68-93 years), recruited from two aged care facilities in Western Australia. PainChek™ assessments were blindly compared with the Abbey Pain Scale. The results showed that PainChek™ was able to distinguish the presence of pain under various clinical testing conditions reflective of rest and movement such as sitting and walking, respectively.

The study is expected to be published in Q1, 2018.


“This study reconfirms the PainChek™ App as a reliable and accurate pain assessment tool for people who are unable to verbalize their pain effectively. We are already receiving an overwhelming positive feedback on the clinical utility of PainChek™ and its impact on residents on a daily basis from our clients in Australia This new publication provides more evidence for the healthcare professional and supports our ongoing commercialization strategies” said Philip Daffas CEO and Managing Director.

The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



PainChek™ artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



PainChek™ six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it's reproducibility, PainChek™ will be able to be used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.

For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235